<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358084</url>
  </required_header>
  <id_info>
    <org_study_id>NGR019</org_study_id>
    <secondary_id>2010-023614-31</secondary_id>
    <nct_id>NCT01358084</nct_id>
  </id_info>
  <brief_title>Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM</brief_title>
  <acronym>NGR019</acronym>
  <official_title>NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MolMed S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MolMed S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to document the efficacy of NGR-hTNF administered as
      maintenance treatment at 0.8 µg/m2 weekly in advanced malignant pleural mesothelioma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First-line treatment of advanced malignant pleural mesothelioma (MPM) is based on six cycles
      of a pemetrexed-based chemotherapy, with a median progression-free survival (PFS) of
      approximately 6 months.However, the median time from completion of first-line treatment to
      initiation of second-line therapy is approximately 3 months. Recent experiences in non-small
      cell lung cancer patients have shown that a maintenance treatment given immediately after
      first-line treatment regimens can improve PFS and survival. Considering the toxicity profile
      of NGR-hTNF characterized by mild-to-moderate constitutional symptoms registered in a phase
      II trial in previously treated MPM patients, as well as the disease control observed in about
      half of the patients and maintained for more than four months and more than nine months in
      the triweekly and weekly cohorts, respectively, seems justified to compare in a randomized
      phase II trial the time-related efficacy of NGR-hTNF against placebo in advanced MPM patients
      who did not progress after six cycles of a standard pemetrexed-based treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">December 5, 2018</completion_date>
  <primary_completion_date type="Actual">December 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>every 6 weeks</time_frame>
    <description>Defined as the time from the date of randomization until disease progression, or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>every 6-12 weeks</time_frame>
    <description>Defined as the time from the date of randomization until the date of death due to any cause or the last date the patient was known to be alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>every 6 weeks</time_frame>
    <description>Assessed according to modified RECIST criteria for MPM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Toxicity according to NCI-CTCAE criteria(version 4.03)</measure>
    <time_frame>during the study</time_frame>
    <description>To evaluate safety and toxicity profile related to NGR-hTNF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment by using a questionnaire according to Lung Cancer Symptom Scale (LCSS)</measure>
    <time_frame>From date of randomization until the end of treatment, assessed every 6 weeks</time_frame>
    <description>To assess changes in quality of life (QoL) in the two treatment arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Advanced Malignant Pleural Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Arm A: NGR-hTNF + Best Supportive Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGR-hTNF + Best Supportive Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo + Best Supportive Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Best Supportive Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NGR-hTNF</intervention_name>
    <description>NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs</description>
    <arm_group_label>Arm A: NGR-hTNF + Best Supportive Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs</description>
    <arm_group_label>Arm B: Placebo + Best Supportive Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <description>Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis</description>
    <arm_group_label>Arm A: NGR-hTNF + Best Supportive Care</arm_group_label>
    <arm_group_label>Arm B: Placebo + Best Supportive Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Histologically or cytological confirmed malignant pleural mesothelioma of any of the
             following subtype: epithelial, sarcomatoid, mixed, or unknown

          -  Patients with non-progressive disease after six cycles of first-line, pemetrexed-based
             regimen administered for advanced or metastatic disease

          -  ECOG Performance Status 0 - 1

          -  Life expectancy of ≥ 12 weeks

          -  Adequate baseline bone marrow, hepatic and renal function, defined as follows:

               1. Neutrophils ≥ 1.5 x 109/L; platelets ≥ 100 x109/L; hemoglobin ≥ 9 g/dL

               2. Bilirubin ≤ 1.5 x ULN

               3. AST and/or ALT ≤ 2.5 x ULN in absence of liver metastasis or ≤ 5 x ULN in
                  presence of liver metastasis

               4. Serum creatinine &lt; 1.5 x ULN

          -  Measurable or non-measurable disease according to malignant pleural
             mesothelioma-modified RECIST criteria

          -  Patients may have had prior therapy providing the following conditions are met:

               -  Surgery: wash-out period of 14 days

               -  Radiation therapy: wash-out period of 28 days

               -  Chemotherapy: wash-out period of 21 days

          -  Patients must give written informed consent to participate in the study

        Exclusion Criteria:

          -  Patients must not receive any other investigational agents while on study

          -  Patients with myocardial infarction within the last six months, unstable angina, New
             York Heart Association (NYHA) grade II or greater congestive heart failure, or serious
             cardiac arrhythmia requiring medication

          -  Uncontrolled hypertension

          -  QTc interval (congenital or acquired) &gt; 450 ms

          -  History or evidence upon physical examination of Central Nervous System disease unless
             adequately treated

          -  Patients with active or uncontrolled systemic disease/infections or with serious
             illness or medical conditions, which is incompatible with the protocol

          -  Known hypersensitivity/allergic reaction to human albumin preparations or to any of
             the excipients

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol

          -  Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Lambiase, MD</last_name>
    <role>Study Director</role>
    <affiliation>MolMed S.p.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH</name>
      <address>
        <city>Bad Berka</city>
        <state>Thuringia</state>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken München-Gauting</name>
      <address>
        <city>München-Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santo Spirito</name>
      <address>
        <city>Casale Monferrato</city>
        <state>Alessandria</state>
        <zip>15033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-IRST</name>
      <address>
        <city>Meldola</city>
        <state>Forlì-Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria San Martino IST Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asl 3 genovese, Ospedale Villa Scassi</name>
      <address>
        <city>Genova</city>
        <zip>16149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Unità Sanitaria locale di Ravenna</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ca' Foncello</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Medical University n.a. I. P. Pavlov</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 19, 2011</study_first_submitted>
  <study_first_submitted_qc>May 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2011</study_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant Pleural Mesothelioma</keyword>
  <keyword>MPM</keyword>
  <keyword>Maintenance treatment</keyword>
  <keyword>NGR-hTNF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

